In normal B cells, antigen receptor-induced NF-kappaB activation requires CARD11, a cytoplasmic scaffolding protein.
CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
Aberrant expression of CARD11 can promote cancer pathogenesis through changes to mTOR signaling and autophagy.
(Will delete Record if Target field = "Delete") Home